Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Shin Kibe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8197-0313; OpenAlex author ID A5009177046. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 10

  1. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
  2. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. First author DOI 10.1016/j.cell.2021.07.020↗
  3. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. Co-author DOI 10.1371/journal.pone.0228015↗
  4. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts. Co-author DOI 10.3892/ijo.2019.4951↗
  5. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Co-author DOI 10.1016/j.canlet.2018.12.005↗
  6. S100P regulates the collective invasion of pancreatic cancer cells into the lymphatic endothelial monolayer. Co-author DOI 10.3892/ijo.2019.4812↗
  7. Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. Co-author DOI 10.1016/j.canlet.2017.10.010↗
  8. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2018.03.031↗
  9. Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6761-6↗
  10. Autophagy inhibition enhances antiproliferative effect of salinomycin in pancreatic cancer cells. Co-author DOI 10.1016/j.pan.2017.08.009↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenoki Ohuchida · 10 shared papers, 2017–2023 · strength 0.84
  2. Kohei Nakata · 9 shared papers, 2017–2023 · strength 0.75
  3. Masafumi Nakamura · 8 shared papers, 2017–2023 · strength 0.69
  4. Toshiya Abe · 8 shared papers, 2017–2023 · strength 0.66
  5. Yoshihiro Miyasaka · 8 shared papers, 2017–2020 · strength 0.59
  6. Takao Ohtsuka · 8 shared papers, 2017–2020 · strength 0.59
  7. Chika Iwamoto · 6 shared papers, 2018–2023 · strength 0.54
  8. Yohei Ando · 7 shared papers, 2017–2020 · strength 0.51
  9. Shin Takesue · 7 shared papers, 2017–2020 · strength 0.51
  10. Yoshinao Oda · 5 shared papers, 2018–2023 · strength 0.50
  11. Kazuhiro Koikawa · 6 shared papers, 2017–2021 · strength 0.42
  12. Hiromichi Nakayama · 6 shared papers, 2017–2020 · strength 0.41
  13. Sho Endo · 5 shared papers, 2017–2019 · strength 0.33
  14. Takashi Okumura · 5 shared papers, 2017–2019 · strength 0.33
  15. Koji Shindo · 3 shared papers, 2019–2020 · strength 0.26
  16. Tomohiko Shinkawa · 2 shared papers, 2020–2023 · strength 0.24
  17. Akiko Sagara · 3 shared papers, 2017–2020 · strength 0.21
  18. Makoto Hashizume · 3 shared papers, 2018–2020 · strength 0.21
  19. Bo Zhang · 1 shared paper, 2023 · strength 0.16
  20. Zilong Yan · 1 shared paper, 2023 · strength 0.16
  21. Noboru Ideno · 1 shared paper, 2023 · strength 0.16
  22. Naoki Ikenaga · 1 shared paper, 2023 · strength 0.16
  23. Shuang Fei · 1 shared paper, 2023 · strength 0.16
  24. Masafumi Nakamura · 2 shared papers, 2018 · strength 0.15
  25. Kun Ping Lu · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.